Kevan C Herold

Summary

Affiliation: Columbia University
Country: USA

Publications

  1. ncbi request reprint Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
    Kevan C Herold
    Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
    N Engl J Med 346:1692-8. 2002
  2. ncbi request reprint Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
    Kevan C Herold
    Department of Medicine, the Naomi Berrie Diabetes Center, and the Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Immunol Res 28:141-50. 2003
  3. ncbi request reprint Treatment of type 1 diabetes with anti-CD3 monoclonal antibody
    Mariela Glandt
    Division of Endocrinology and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, NY and the Pacific Northwest Research Institute, Seattle, WA
    Rev Endocr Metab Disord 4:361-8. 2003
  4. pmc Achieving antigen-specific immune regulation
    Kevan C Herold
    Naomi Berrie Diabetes Center, Division of Endocrinology and Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Invest 113:346-9. 2004
  5. pmc Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
    Damien Bresson
    Department of Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    J Clin Invest 116:1371-81. 2006
  6. ncbi request reprint Achieving antigen-specific tolerance in diabetes: regulating specifically
    Wei Chen
    Naomi Berrie Diabetes Center and the Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Int Rev Immunol 24:287-305. 2005
  7. pmc Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)
    Kevan C Herold
    Naomi Berrie Diabetes Center, Department of Medicine and Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Invest 111:409-18. 2003
  8. ncbi request reprint A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
    Kevan C Herold
    Associate Professor of Medicine, Columbia University, PH10 105, 630 W 168th St, New York, NY 10032, USA
    Diabetes 54:1763-9. 2005
  9. ncbi request reprint Treatment of type 1 diabetes mellitus to preserve insulin secretion
    Kevan C Herold
    Division of Endocrinology, Department of Medicine, Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Endocrinol Metab Clin North Am 33:93-111, ix. 2004
  10. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
    Kevan C Herold
    Naomi Berrie Diabetes Center and the Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York 10032, USA
    N Engl J Med 346:1692-8. 2002
    ..Preclinical studies suggested that a monoclonal antibody against CD3 could reverse hyperglycemia at presentation and induce tolerance to recurrent disease...
  2. ncbi request reprint Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
    Kevan C Herold
    Department of Medicine, the Naomi Berrie Diabetes Center, and the Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Immunol Res 28:141-50. 2003
    ..The induction of cells with a regulatory phenotype may account for the ability of anti-CD3 MAb to induce immune regulation...
  3. ncbi request reprint Treatment of type 1 diabetes with anti-CD3 monoclonal antibody
    Mariela Glandt
    Division of Endocrinology and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, NY and the Pacific Northwest Research Institute, Seattle, WA
    Rev Endocr Metab Disord 4:361-8. 2003
  4. pmc Achieving antigen-specific immune regulation
    Kevan C Herold
    Naomi Berrie Diabetes Center, Division of Endocrinology and Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Invest 113:346-9. 2004
    ..The antigen-specific response characterized by release of a regulatory cytokine suggests a mechanism for the control of autoimmunity that is initiated at the time of antigen presentation...
  5. pmc Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs
    Damien Bresson
    Department of Developmental Immunology 3, La Jolla Institute for Allergy and Immunology, San Diego, California 92121, USA
    J Clin Invest 116:1371-81. 2006
    ..Since Tregs act site-specifically, this strategy should also be expected to reduce the potential for systemic side effects...
  6. ncbi request reprint Achieving antigen-specific tolerance in diabetes: regulating specifically
    Wei Chen
    Naomi Berrie Diabetes Center and the Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    Int Rev Immunol 24:287-305. 2005
    ....
  7. pmc Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala)
    Kevan C Herold
    Naomi Berrie Diabetes Center, Department of Medicine and Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Invest 111:409-18. 2003
    ..It leads to the generation of T cells that might inhibit the autoimmune response and may be involved in the beneficial effect on beta cell destruction in Type 1 diabetes...
  8. ncbi request reprint A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes
    Kevan C Herold
    Associate Professor of Medicine, Columbia University, PH10 105, 630 W 168th St, New York, NY 10032, USA
    Diabetes 54:1763-9. 2005
    ....
  9. ncbi request reprint Treatment of type 1 diabetes mellitus to preserve insulin secretion
    Kevan C Herold
    Division of Endocrinology, Department of Medicine, Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Endocrinol Metab Clin North Am 33:93-111, ix. 2004
  10. ncbi request reprint Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, P O Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 30:38-42. 2007
    ....
  11. pmc TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs
    Brygida Bisikirska
    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    J Clin Invest 115:2904-13. 2005
    ..Foxp3 was also induced on CD8+ T cells in patients during mAb treatment, which suggests a potential mechanism of the anti-CD3 mAb immune modulatory effects involving induction of a subset of regulatory CD8+ T cells...
  12. ncbi request reprint Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes
    Brygida C Bisikirska
    Department of Medicine, PH 10 105, 630 W 168th Street, New York, NY 10032, USA
    Ann N Y Acad Sci 1037:1-9. 2004
    ..These initial studies have shown clinical efficacy of treatment with anti-CD3 mAb and suggest a novel mechanism that may account for the lasting effects of treatment...
  13. pmc Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors
    Salma Begum
    Department of Genetics and Development, HHSC 1402, Columbia University, New York, New York 10032, USA
    Endocrinology 150:4512-20. 2009
    ....
  14. ncbi request reprint Insulin secretion in type 1 diabetes
    Chynna Steele
    Department of Medicine, Division of Endocrinology, and the Naomi Berrie Diabetes Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA
    Diabetes 53:426-33. 2004
    ....
  15. pmc Effects of controlled-release alpha lipoic acid in lean, nondiabetic patients with polycystic ovary syndrome
    Umesh Masharani
    Department of Medicine, University of California, San Francisco, Diabetes Center, San Francisco, California 94143, USA
    J Diabetes Sci Technol 4:359-64. 2010
    ..The purpose of this study was to determine whether a preparation of controlled-release alpha lipoic acid (CRLA) influences features of the polycystic ovary syndrome (PCOS)...
  16. ncbi request reprint Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1
    Jay M Sosenko
    Division of Endocrinology, University of Miami, PO Box 016960 D110, Miami, FL 33101, USA
    Diabetes Care 29:643-9. 2006
    ..The goal of this study was to utilize data from the Diabetes Prevention Trial-Type 1 (DPT-1) to obtain a picture of the metabolic progression to type 1 diabetes over a period of approximately 2.5 years before its diagnosis...
  17. ncbi request reprint Autoimmunity and beta cell regeneration in mouse and human type 1 diabetes: the peace is not enough
    Vitaly Ablamunits
    Section of Immunobiology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06520, USA
    Ann N Y Acad Sci 1103:19-32. 2007
    ..Additional therapeutic modalities capable of stimulating beta cell regeneration in the absence of active autoimmune destruction are urgently needed...
  18. ncbi request reprint Drug insight: New immunomodulatory therapies in type 1 diabetes
    Simona Cernea
    Columbia University, New York, NY, USA
    Nat Clin Pract Endocrinol Metab 2:89-98. 2006
    ..Ultimately, preservation and even improvement in beta-cell mass is the goal of therapy. The means needed to achieve this will depend on the timing and mechanisms of the immune intervention and might require combinations of agents...
  19. ncbi request reprint Natural history of beta-cell function in type 1 diabetes
    Nicole A Sherry
    Naomie Berrie Diabetes Center and Department of Pediatrics, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, New York 10032, USA
    Diabetes 54:S32-9. 2005
    ..Understanding the modifiers and predictors of beta-cell function would allow targeting immunological approaches to those individuals most likely to benefit from therapy...
  20. ncbi request reprint Regulatory T cells and type 1 diabetes
    Brygida C Bisikirska
    Division of Endocrinology, Naomi Berrie Diabetes Center, Department of Medicine, College of Physicians and Surgeons, Columbia University, Room 10 105, 630 W 168th Street, New York, NY 10032, USA
    Curr Diab Rep 5:104-9. 2005
    ..These cells may be expanded by immune therapy, suggesting the possible development of adoptive immune therapy to transfer regulation with the cells...
  21. ncbi request reprint Treatment of type 1 diabetes with anti-T-cell agents: from T-cell depletion to T-cell regulation
    Mariela Glandt
    Department of Medicine, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Avenue, New York, NY 10032, USA
    Curr Diab Rep 4:291-7. 2004
    ..Data now suggest that efficacy and duration of the effects of anti-T-cell drugs can be enhanced when the agents provoke immune modulation rather than depletion of effector cells...
  22. ncbi request reprint A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene
    Marie King
    Department of Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01655, USA
    Clin Immunol 126:303-14. 2008
    ..These data suggest that humanized NOD-scid Il2rgamma(null) mice may represent an important surrogate for investigating in vivo mechanisms of human islet allograft rejection...
  23. ncbi request reprint Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products
    Yali Chen
    Naomi Berrie Diabetes Center, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
    J Immunol 173:1399-405. 2004
    ..5. We conclude that RAGE/ligand interactions are involved in the differentiation of T cells to a mature pathogenic phenotype during the late stages of the development of diabetes...
  24. pmc Immunotherapy of type 1 diabetes: where are we and where should we be going?
    Xunrong Luo
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Immunity 32:488-99. 2010
    ....
  25. ncbi request reprint C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001
    Jerry P Palmer
    Department of Medicine, University of Washington, and DVA Puget Sound Health Care System, Seattle, Washington 98108, USA
    Diabetes 53:250-64. 2004
    ..The development of therapies for addressing this important unmet clinical need will be facilitated by trials that are carefully designed with beta-cell function as determined by C-peptide measurement as the primary efficacy outcome...
  26. doi request reprint Functional human to mouse adipose tissue xenotransplantation
    Vitaly Ablamunits
    Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
    J Endocrinol 212:41-7. 2012
    ..Transfer of 2×10(7) human mononuclear cells to reject WAT as an allograft was ineffective and resulted only in some reduction of circulating leptin and a limited damage to the WAT grafts followed by the loss of human leukocytes...
  27. ncbi request reprint Islet transplantation for type 1 diabetes--where should we go?
    Piotr Witkowski
    Columbia University, New York, NY, USA
    Nat Clin Pract Endocrinol Metab 3:2-3. 2007
  28. ncbi request reprint RAGE: a journey from the complications of diabetes to disorders of the nervous system - striking a fine balance between injury and repair
    Ling Ling Rong
    Department of Surgery, Columbia University Medical Center, NY 10032, USA
    Restor Neurol Neurosci 23:355-65. 2005
    ..Experimental evidence supports the premise that RAGE bears both homeostatic and injurious properties in the nervous system, thereby highlighting "yin/yang" features of this receptor and its ligand families...
  29. pmc Influence of gender on the relationship between insulin sensitivity, adiposity, and plasma lipids in lean nondiabetic subjects
    Umesh Masharani
    Division of Endocrinology and Metabolism, Department of Medicine, University of California San Francisco, San Francisco, CA 94115, USA
    Metabolism 58:1602-8. 2009
    ..These results both highlight sex differences in the associations between insulin resistance, regional adipose stores, and lipids values and emphasize the importance of adipose stores on the development of an individual's lipid profile...
  30. ncbi request reprint Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells
    Nicole A Sherry
    Department of Immunobiology, Yale University, New Haven, CT 06520, USA
    Endocrinology 148:5136-44. 2007
    ..This combinatorial approach may be useful in treatment of patients with new-onset T1DM...
  31. ncbi request reprint Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes
    Nicole A Sherry
    Section of Immunobiology, Yale University, 300 Cedar St, Room S155B, New Haven, CT 06520, USA
    Diabetes 55:3238-45. 2006
    ..Correction of the beta-cell loss in type 1 diabetes will, therefore, require strategies that target both the immunologic and cellular mechanisms that destroy and maintain beta-cell mass...
  32. ncbi request reprint Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
    Vicki Seyfert-Margolis
    Immune Teolerance Network, Bethesda, Maryland, USA
    Diabetes 55:2588-94. 2006
    ..They may be useful for assessment of cellular autoimmune responses involved in type 1 diabetes...
  33. ncbi request reprint A patient with type B insulin resistance syndrome, responsive to immune therapy
    Kathleen A Page
    Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520 8020, USA
    Nat Clin Pract Endocrinol Metab 3:835-40. 2007
    ..She remained hyperglycemic (blood glucose levels 16.7-27.8 mmol/l), despite intravenous insulin at doses as high as 30,000 U/day...
  34. pmc RAGE ligation affects T cell activation and controls T cell differentiation
    Yali Chen
    Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Immunol 181:4272-8. 2008
    ..We conclude that activation of RAGE on T cells is involved in early events that lead to differentiation of Th1(+) T cells...
  35. ncbi request reprint Continuous subcutaneous insulin infusion in older patients with type 1 diabetes
    Leigh Siegel-Czarkowski
    Diabetes Care 27:3022-3. 2004
  36. ncbi request reprint Pancreatic islets activate portal vein endothelial cells in vitro
    Magali J Fontaine
    Department of Pathology, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Ann Clin Lab Sci 32:352-61. 2002
    ..Neither lymphocyte proliferation nor cytotoxicity could be enhanced in response to enhanced MHC Class I and ICAM-1 expression, which was associated instead with non-specific inflammatory cytokine release...
  37. doi request reprint Prevention of type 1 diabetes: the time has come
    Jennifer Sherr
    Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA
    Nat Clin Pract Endocrinol Metab 4:334-43. 2008
    ..In this Review we discuss risk-stratification techniques and how they are applied, other diagnostic criteria, and outcomes from diabetes-prevention trials...